---
title: "This Lumentum Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297513448.md"
description: "Top Wall Street analysts initiated coverage on several stocks this Monday. Evercore ISI's Amit Daryanani started covering Lumentum Holdings with an Outperform rating and a $1,100 price target. BTIG's Ryan Zimmerman initiated Smith & Nephew with a Neutral rating. Morgan Stanley's Judah Frommer covered Attovia Therapeutics with an Overweight rating and a $39 target. Roth Capital's Eric Handler initiated Ticketplus with a Buy rating and a $14 target. Stifel's James Condulis started Braveheart Bio with a Buy rating and a $45 target."
datetime: "2026-08-31T11:46:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297513448.md)
  - [en](https://longbridge.com/en/news/297513448.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297513448.md)
generator: "portal-rs"
---

# This Lumentum Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

-   Evercore ISI Group analyst Amit Daryanani initiated coverage on **Lumentum Holdings Inc** (NASDAQ:LITE) with an Outperform rating and announced a price target of $1,100. Lumentum closed at $895.00 on Friday. See how other analysts view this stock.
-   BTIG analyst Ryan Zimmerman initiated coverage on **Smith & Nephew PLC** (NYSE:SNN) with a Neutral rating. Smith & Nephew shares closed at $28.97 on Friday. See how other analysts view this stock.
-   Morgan Stanley analyst Judah Frommer initiated coverage on **Attovia Therapeutics Inc** (NASDAQ:ATTO) with an Overweight rating and announced a price target of $39. Attovia Therapeutics closed at $20.70 on Friday. See how other analysts view this stock.
-   Roth Capital analyst Eric Handler initiated coverage on **Ticketplus Ltd.** (AMEX:TP) with a Buy rating and announced a price target of $14. Ticketplus shares closed at $7.83 on Friday. See how other analysts view this stock.
-   Stifel analyst James Condulis initiated coverage on **Braveheart Bio, Inc.** (NASDAQ:BRVE) with a Buy rating and announced a price target of $45. Braveheart Bio closed at $27.44 on Friday. See how other analysts view this stock.

Considering buying LITE stock? Here’s what analysts think:

*Photo via Shutterstock*

### Related Stocks

- [TP.US](https://longbridge.com/en/quote/TP.US.md)
- [BRVE.US](https://longbridge.com/en/quote/BRVE.US.md)
- [LITE.US](https://longbridge.com/en/quote/LITE.US.md)
- [ATTO.US](https://longbridge.com/en/quote/ATTO.US.md)
- [SNN.US](https://longbridge.com/en/quote/SNN.US.md)
- [LITU.US](https://longbridge.com/en/quote/LITU.US.md)
- [LITX.US](https://longbridge.com/en/quote/LITX.US.md)
- [LITZ.US](https://longbridge.com/en/quote/LITZ.US.md)

## Related News & Research

- [Jae Kim Sells 12,000 Shares of Lumentum (NASDAQ:LITE) Stock](https://longbridge.com/en/news/297258704.md)
- [Vincent Retort Sells 38,663 Shares of Lumentum (NASDAQ:LITE) Stock](https://longbridge.com/en/news/297258706.md)
- [Michael Hurlston Sells 548 Shares of Lumentum (NASDAQ:LITE) Stock](https://longbridge.com/en/news/297314076.md)
- [Attovia Therapeutics, Inc. (ATTO) Initiated with a Buy at RBC Capital](https://longbridge.com/en/news/297470988.md)
- [TipRanks Analyst Salveen Richter Reiterates Buy on Braveheart Bio, Sets $48 12-Month Target on Strong HCM Opportunity for Lead Asset BHB-1893](https://longbridge.com/en/news/297471640.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**